Haploidentical bone marrow and stem cell transplantation: Experience with post-transplantation cyclophosphamide

Tara M. Robinson, Paul V. O'Donnell, Ephraim J. Fuchs, Leo Luznik

Research output: Contribution to journalReview articlepeer-review

Abstract

Allogeneic blood or bone marrow transplantation (BMT) is a potentially curative therapy for high-risk hematologic malignancies not curable by standard chemotherapy, but the procedure is limited by the availability of human leukocyte antigen-matched donors for many patients, as well as toxicities including graft-versus-host disease (GVHD). Our group has developed the use of high-dose post-transplantation cyclophosphamide (PTCy) to selectively remove alloreactive T cells without compromising engraftment. This protocol has allowed for successful transplantation of human leukocyte antigen (HLA)-haploidentical (haplo) grafts, thus expanding the donor pool for the many patients who would not otherwise be a candidate for this life-saving procedure. In this review we will summarize the data that led to the development of PTCy, then focus on the outcomes of haploBMT trials with PTCy across different transplant platforms for patients with malignant hematologic diseases, and finally we will discuss emerging evidence that suggests equivalency of haploBMT with PTCy compared with more traditional transplants.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalSeminars in Hematology
Volume53
Issue number2
DOIs
StatePublished - Apr 1 2016

Keywords

  • Bone marrow transplant
  • GVHD prophylaxis
  • Haploidentical
  • Post-transplant cyclophosphamide

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Haploidentical bone marrow and stem cell transplantation: Experience with post-transplantation cyclophosphamide'. Together they form a unique fingerprint.

Cite this